ArticleMaterials horizons2021
Erythrocyte-mediated delivery of bioorthogonal nanozymes for selective targeting of bacterial infections.
Article in Materials horizons, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 37 citations in OpenAlex.
- Review
- Endophyte-mediated biosynthesis of biogenic nanoparticles: mechanisms and biomedical applications.Archives of microbiology · 2026Review
- Stimuli-responsive nanozymes for wound healing: From design strategies to therapeutic advances.Materials today. Bio · 2025Review
- Bioorthogonal catalysis for antimicrobial therapy.MedMat · 2024Article
- Modular Fabrication of Bioorthogonal Nanozymes for Biomedical Applications.Advanced materials (Deerfield Beach, Fla.) · 2024Review
- Modulation of Gold Nanoparticle Ligand Structure-Dynamic Relationships Probed Using Solution NMR.ACS nanoscience Au · 2024Article
- Polarization of macrophages to an anti-cancer phenotype throughChemical science · 2024Article
- Red blood cells: a potential delivery system.Journal of nanobiotechnology · 2023Review
- Bioorthogonal nanozymes for breast cancer imaging and therapy.Journal of controlled release : official journal of the Controlled Release Society · 2023Article
- Inorganic nanoparticles as scaffolds for bioorthogonal catalysts.Advanced drug delivery reviews · 2023Review
- Biodegradable Antibacterial Bioorthogonal Polymeric Nanocatalysts Prepared by Flash Nanoprecipitation.ACS applied materials & interfaces · 2023Article
- Red Blood Cell Inspired Strategies for Drug Delivery: Emerging Concepts and New Advances.Pharmaceutical research · 2022Review
- Enhanced Design of Gold Catalysts for Bioorthogonal Polyzymes.Materials (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
Bioorthogonal transformation of imaging and therapeutic substrates using transition metal catalysts (TMCs) provides a toolkit with diverse applications in biomedicine. Controlled localization of bioorthogonal catalysis is key for enhancing their therapeutic efficacy by minimizing off-target effects. Red blood cells (RBCs) are highly biocompatible and are susceptible to hemolysis by bacterial toxins, providing them with intrinsic targeting to bacterial infections. A hitchhiking strategy using RBCs is reported, that activates bioorthogonal catalysis at infection sites. A library of nanoparticles embedded with TMCs (nanozymes) featuring diverse functional groups with different binding ability to RBCs is generated. These engineered nanozymes bind to RBCs and subsequently release upon hemolysis by bacterial toxins, resulting in selective accumulation at the site of bacterial infections. The antimicrobial action is specific: catalytic activation of pro-antibiotics eradicated pathogenic biofilms without harming non-virulent bacterial species.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.